2 result(s) displayed (1 - 2 of 2):

Bristol's $2.4B Medarex buy advances trend (from Corporate Dealmaker)

Before releasing second-quarter earnings, cash-rich Bristol-Myers Squibb Co. (NYSE:BMY) said late Wednesday it's acquiring Medarex Inc. (NASDAQ: MEDX) for $2.4 billion, extending a string of recent deals in the oncology sector.Bristol chairman and CEO James Cornelius said in a statement, "Medarex's technology platform, people and pipeline provide a strong complement...

Posted on July 23, 2009 9:38 AM

Oncology M&A could save lives (from Corporate Dealmaker)

News of Celldex Therapeutics Inc. (NASDAQ:CLDX) acquiring CuraGen Corp. (NASDAQ:CRGN) for $94.5 million not only highlights a dealmaking trend we're tracking but signifies the need for a broader consolidation that could literally save lives.The acquisition of CuraGen will add a portfolio of oncology-focused, fully-owned antibodies to Celldex's precision-targeted immunotherapy platform....

Posted on May 29, 2009 12:30 PM